Roy­al­ty Phar­ma gets more com­pe­ti­tion as a pri­vate eq­ui­ty firm launch­es $725M roy­al­ty-buy­ing fund

Pablo’s got some peers.

Twen­ty-five years af­ter Mex­i­can bil­lion­aire Pablo Legor­re­ta start­ed buy­ing up fu­ture roy­al­ties on ap­proved drugs — and eight months af­ter he turned that in­to a record-set­ting $2.2 bil­lion IPO for Roy­al­ty Phar­ma— an­oth­er firm is rais­ing large sums to do the same thing. Sagard Hold­ings, the Cana­di­an in­vest­ment firm, raised $725 mil­lion for a new fund, known as Sagard Health­care Roy­al­ty Part­ners, that will pur­chase roy­al­ties in drugs, di­ag­nos­tics and med­ical prod­ucts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER